Meghalaya Magazine

Achondroplasia Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies – Ascendis Pharma, BridgeBio, QED Therapeutics, Ribomic Inc.

 Breaking News
  • No posts were found

Achondroplasia Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies – Ascendis Pharma, BridgeBio, QED Therapeutics, Ribomic Inc.

January 12
22:45 2023
Achondroplasia Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies - Ascendis Pharma, BridgeBio, QED Therapeutics, Ribomic Inc.
The Achondroplasia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Achondroplasia pipeline products will significantly revolutionize the Achondroplasia market dynamics.

DelveInsight’s “Achondroplasia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Achondroplasia, historical and forecasted epidemiology as well as the Achondroplasia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Achondroplasia market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Achondroplasia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Achondroplasia Market Insights

 

Achondroplasia Overview

Achondroplasia is a rare genetic disorder resulting in short-limb skeletal dysplasia occurring in approximately 1 in 20,000-30,000 live births. This genetic disorder is caused by a mutation in the fibroblast growth factor receptor 3 (FGFR3) gene which occurs as a result of a spontaneous genetic mutation in approximately 80 percent of patients and in the remaining 20 percent it is inherited from a parent.

 

Some of the key facts of the Achondroplasia Market Report: 

  • The Achondroplasia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • According to National organization for rare disorders (NORD) the worldwide estimated incidence of achondroplasia ranges from about 1 in 15,000 to 1 in 35,000 births
  • According to American journal of Medical Genetics it was estimated that 20.2% of familial cases and 10% of cases with Achondroplasia had associated major congenital anomalies
  • According to European population based epidemiological study provided by the European Surveillance of Congenital Anomalies (EUROCAT) network research the prevalence of achondroplasia is 3.7 per birth of 100,000 population
  • Achondroplasia is caused by mutations (G1138A and G1138C) in the fibroblast growth factor receptor 3 (FGFR3) gene, encoding a receptor regulating the linear bone growth
  • Key Achondroplasia Companies: Ascendis Pharma, BridgeBio, QED Therapeutics, Ribomic Inc., and others
  • Key Achondroplasia Therapies: TransConCNP, Infigratinib, Recifercept, and others

 

Get a Free sample for the Achondroplasia Market Report – 

https://www.delveinsight.com/sample-request/achondroplasia-market

 

Key benefits of the Achondroplasia Market report:

  1. Achondroplasia market report covers a descriptive overview and comprehensive insight of the Achondroplasia Epidemiology and Achondroplasia market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Achondroplasia market report provides insights on the current and emerging therapies.
  3. Achondroplasia market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Achondroplasia market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Achondroplasia market.

 

Download the report to understand which factors are driving Achondroplasia epidemiology trends @ Achondroplasia Epidemiological Insights 

 

Achondroplasia Market  

The dynamics of the Achondroplasia market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. 

 

Achondroplasia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Achondroplasia Epidemiology Segmentation:

The Achondroplasia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Achondroplasia
  • Prevalent Cases of Achondroplasia by severity
  • Gender-specific Prevalence of Achondroplasia
  • Diagnosed Cases of Episodic and Chronic Achondroplasia

 

Achondroplasia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Achondroplasia market or expected to get launched during the study period. The analysis covers Achondroplasia market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Achondroplasia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Discover more about therapies set to grab major Achondroplasia market share @ Achondroplasia market forecast 

 

Achondroplasia Therapies and Key Companies

  • TransConCNP: Ascendis Pharma
  • Infigratinib: BridgeBio/QED Therapeutics
  • Recifercept: Ribomic Inc.

 

Scope of the Achondroplasia Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Achondroplasia Companies: Ascendis Pharma, BridgeBio, QED Therapeutics, Ribomic Inc., and others
  • Key Achondroplasia Therapies: TransConCNP, Infigratinib, Recifercept, and others
  • Achondroplasia Therapeutic Assessment: Achondroplasia current marketed and Achondroplasia emerging therapies
  • Achondroplasia Market Dynamics: Achondroplasia market drivers and Achondroplasia market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Achondroplasia Unmet Needs, KOL’s views, Analyst’s views, Achondroplasia Market Access and Reimbursement 

 

Table of Contents 

1. Achondroplasia Market Report Introduction

2. Executive Summary for Achondroplasia

3. SWOT analysis of Achondroplasia

4. Achondroplasia Patient Share (%) Overview at a Glance

5. Achondroplasia Market Overview at a Glance

6. Achondroplasia Disease Background and Overview

7. Achondroplasia Epidemiology and Patient Population

8. Country-Specific Patient Population of Achondroplasia 

9. Achondroplasia Current Treatment and Medical Practices

10. Achondroplasia Unmet Needs

11. Achondroplasia Emerging Therapies

12. Achondroplasia Market Outlook

13. Country-Wise Achondroplasia Market Analysis (2019–2032)

14. Achondroplasia Market Access and Reimbursement of Therapies

15. Achondroplasia Market Drivers

16. Achondroplasia Market Barriers

17.  Achondroplasia Appendix

18. Achondroplasia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about Achondroplasia treatment, visit @ Achondroplasia Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Categories